ArticleTrials2026
Assessing a biomarker platform for stratifying indeterminate pulmonary nodules, protocol for the SPOT IT randomized trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06638398 (Assessing a Biomarker Platform for Stratifying Indeterminate Pulmonary Nodules - The SPOT IT Platform Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing a Biomarker Platform for Stratifying Indeterminate Pulmonary Nodules - The SPOT IT Platform Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundMillions of lung nodules are detected every year during routine computed tomography imaging. While most are benign, some represent early-stage lung cancer and require prompt diagnosis as survival worsens with advanced stages. The Lung Cancer Prediction score is a computed tomography-based radiomic biomarker used to risk-stratify pulmonary nodules. Observational studies have shown promising results, but it remains unclear if the use of this biomarker improves patient management.
methodsSPOT IT is a multicenter, open-label, randomized controlled superiority trial. Adult patients (35 years and older) referred for evaluation of an incidentally detected lung nodule 8-30 mm in size who meet all eligibility criteria are currently being enrolled. Participants are randomized in a 1:1 ratio to receive either usual care combined with the Lung Cancer Prediction score or usual care alone. Randomization is conducted using permuted blocks of variable size, stratified by study center and nodule size (≤1.5 cm, >1.5 cm). The primary outcome is appropriate initial nodule management, defined as imaging surveillance for benign nodules and additional diagnostic procedures or definitive therapy for malignant nodules. Secondary outcomes include change in management, unnecessary invasive procedures for benign nodules, and time to diagnosis for malignant nodules. The study was approved by the Vanderbilt University Medical Center (single Institutional Review Board) and is being conducted with waiver of consent. Enrollment began in October 2024 and approximately 400 patients are expected to be enrolled by the time of completion. DISCUSSION: SPOT IT is an ongoing multicenter randomized controlled trial assessing the impact of a commercially available radiomic prediction score on patient management. Results from this trial might help inform the care of patients with pulmonary nodules and clarify the role of the biomarker in routine clinical practice.
trial registrationThe study was registered in ClinicalTrials.gov (NCT06638398) prior to opening. Registered on October 09 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.